Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Operations [Abstract]
Revenue from product sales	$ 153
Cost of sales	8,355	13
Gross loss	(8,202)	(13)
Selling, general and administrative expenses	12,167	12,795
Research and development expenses	9,021	7,171
Operating loss	(29,390)	(19,979)
Other income (expense)
Warrant revaluation income (expense)	8,725	(4,763)
Derivative revaluation expense	(23)	(5,451)
Interest expense	(1,016)	(1,062)
Loss on extinguishment of debt	(4,421)
Loss from continuing operations before income taxes	(26,125)	(31,255)
Deferred tax benefit	2,500
Loss from continuing operations	(23,626)	(31,255)
Loss from discontinued operations	(11)
Gain on sale of discontinued operations, net of tax	467	(95)
Net loss	(23,170)	(31,350)
Net income attributable to noncontrolling interest	(24)	(18)
Net loss attributable to Fibrocell Science, Inc. common shareholders	$ (23,194)	$ (31,368)
Per share information:
Loss from continuing operations - basic and diluted	$ (0.10)	$ (0.57)
Loss from discontinued operations - basic and diluted
Net loss per common share - basic and diluted	$ (0.10)	$ (0.57)
Weighted average number of basic and diluted common shares outstanding	224,127,430	54,857,520